Tumors are dynamic pseudoorgans that contain numerous cell types interacting to create a
unique physiology. Within this network, the malignant cells encounter many challenges and …

Pancreatic ductal adenocarcinoma is on pace to become the second leading cause of
cancer-related death. The high mortality rate results from a lack of methods for early …

Renin-angiotensin system (RAS) inhibitors (RASi)—widely prescribed for the treatment of
cardiovascular diseases—have considerable potential in oncology. The RAS plays a crucial …

The principles of engineering and physics have been applied to oncology for nearly 50
years. Engineers and physical scientists have made contributions to all aspects of cancer …

How can we treat cancer more effectively? Traditionally, tumours from the same anatomical
site are treated as one tumour entity. This concept has been challenged by recent …

Myeloid-derived suppressor cells (MDSC) promote tumor growth by blocking anti-tumor T
cell responses. Recent reports show that MDSC increase fatty acid uptake and fatty acid …

Arginine metabolism has been a key catabolic and anabolic process throughout the
evolution of the immune response. Accruing evidence indicates that arginine-catabolizing …

The relationship between inflammation and cancer has been recognized since the 17th
century, 1 and we now know much about the cells, cytokines and physiological processes …

The tumor microenvironment (TME) in pancreatic ductal adenocarcinoma (PDA) is
characterized by immune tolerance, which enables disease to progress unabated by …

Solid tumor growth and metastasis require the interaction of tumor cells with the surrounding
tissue, leading to a view of tumors as tissue-level phenomena rather than exclusively cell …